It is a therapeutic target for the treatment of short bowel syndrome (SBS), and the GLP-2 analog, teduglutide, is on the market for the management of SBS (34). The gene discussed is GCG; the disease is macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.